| Date | Time | Source | Headline | Symbol | Company |
| 07/09/2024 | 1:11AM | Alliance News |  IN BRIEF: Regeneron says second quarter results to include R&D charge | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 07/03/2024 | 5:46AM | Alliance News | EU approves Sanofi drug Dupixent for chronic lung disease | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 01/26/2024 | 4:07PM | Alliance News | Sanofi and Regeneron celebrate Dupixent's FDA approval | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 12/11/2023 | 2:25PM | Alliance News | Leading pharmaceutical firms highlight positive trial data on lymphoma | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 09/16/2022 | 12:46AM | Alliance News | Regeneron, Sanofi drug effective for young children with severe eczema | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 09/09/2022 | 1:40AM | Alliance News | Regeneron shares surge on positive Eylea trial data | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 06/02/2022 | 10:18AM | Alliance News | Sanofi grants Regeneron global license for cancer treatment Libtayo | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 05/31/2022 | 1:54AM | Alliance News | US FDA accepts Regeneron and Sanofi's Dupixent for priority review | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 03/28/2022 | 1:18AM | Alliance News | IN BRIEF: Sanofi, Regeneron hail positive results in prurigo nodularis | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 02/28/2022 | 1:21AM | Alliance News | Sanofi and Regeneron note positive new data for Dupixent | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 02/18/2022 | 5:26AM | Alliance News | Regeneron and Sanofi stop trial of skin condition treatment Dupixent | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 01/19/2022 | 2:32AM | Alliance News | Sanofi and Regeneron's Dupixent meets endpoints for skin treatment | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 11/12/2021 | 10:54AM | Alliance News | TOP NEWS: Roche and Regeneron Covid antibody cocktail approved in EU | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 10/25/2021 | 1:50AM | Alliance News | Sanofi and Regeneron's Dupixent trial meets primary endpoints | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 10/14/2021 | 8:18AM | Alliance News | US FDA accepts Regeneron's REGEN-COV application for priority review | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 09/30/2021 | 1:36AM | Alliance News | Regeneron, Roche drug cocktail reduces Covid-19 viral load - UK study | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 08/30/2021 | 2:23AM | Alliance News | Sanofi, Regeneron's Dupixent works for children with atopic dermatitis | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 07/27/2021 | 7:56AM | Alliance News | AstraZeneca partners with Regeneron to research obesity treatment | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 07/20/2021 | 1:58AM | Alliance News | Roche and Regeneron's Covid antibody cocktail gets Japan approval | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 06/28/2021 | 1:16AM | Alliance News | Sanofi, Regeneron report well-established safety profile of Dupixent | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 06/25/2021 | 1:48AM | Alliance News | Sanofi and Regeneron's cancer treatment Libtayo gets approval in EU | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 03/23/2021 | 3:26AM | Alliance News | TOP NEWS: Novartis, Regeneron Covid antibody cocktail excels in trials | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 03/15/2021 | 5:20AM | Alliance News | Regeneron, Sanofi report positive phase three trial results of Libtayo | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 02/26/2021 | 12:25PM | Alliance News | EU Medicines Regulator Approves Regeneron Coronavirus Therapy | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 02/25/2021 | 9:05AM | Alliance News | Roche, Regeneron Note Positive Findings For REGEN-COV In Covid-19 | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 02/22/2021 | 3:13PM | Alliance News | IN BRIEF: Sanofi, Regeneron Get US FDA Approval For Lung Cancer Drug | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 01/13/2021 | 1:24AM | Alliance News | Roche Says US To Buy Extra Doses Of Regeneron's Covid Antibody Coctail | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 12/01/2020 | 5:27PM | Alliance News | Regeneron Pharmaceuticals Developing Nasal Spray To Prevent Covid-19 | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 11/30/2020 | 4:59AM | Alliance News | Sanofi And Regeneron Announce New Dupixent Approval In Children | LSE:0R2M | Regeneron Pharmaceuticals Inc |
| 10/26/2020 | 8:52AM | Alliance News | Sanofi, Regeneron Say Dupixent Lowers Esophagitis Symptoms | LSE:0R2M | Regeneron Pharmaceuticals Inc |